Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents

Autor(es):Mostrar menos -

Dos Santos-Junior, Amilton ; Henriques, Taciane Barbosa ; de Mello, Maricilda Palandi ; Della Torre, Osmar Henrique ; Paes, Lucia Arisaka ; Ferreira-Neto, Adriana Perez ; Sewaybricker, Leticia Esposito ; Fontana, Thiago Salum ; Rubello Valler Celeri, Eloisa Helena ; Guerra-Junior, Gil ; Dalgalarrondo, Paulo

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; v. 2016, p. 10-pg., 2016-01-01.

Resumo

Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8-20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations. (AU)

• Processo FAPESP: 12/14005-1 - Farmacogenética da resposta da risperidona em uso isolado ou não no tratamento de transtornos mentais entre 10 e 20 anos de idade
• Beneficiário: Gil Guerra Júnior
• Modalidade de apoio: Auxílio à Pesquisa - Regular